Seres Therapeutics, Inc.
9
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
11.1%
1 terminated/withdrawn out of 9 trials
87.5%
+1.0% vs industry average
22%
2 trials in Phase 3/4
86%
6 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT
Role: lead
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
Role: collaborator
Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
Role: lead
ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection
Role: lead
ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
Role: lead
SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence
Role: lead
A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis
Role: lead
A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
Role: lead
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
Role: lead
All 9 trials loaded